ISSN 1725-2423 |
||
Official Journal of the European Union |
C 289 |
|
English edition |
Information and Notices |
Volume 47 |
Notice No |
Contents |
page |
|
I Information |
|
|
Commission |
|
2004/C 289/1 |
||
2004/C 289/2 |
Prior notification of a concentration (Case COMP/M.3630 — Veolia/BVAG) — Candidate case for simplified procedure ( 1 ) |
|
2004/C 289/3 |
Prior notification of a concentration (Case COMP/M.3612 — Henkel/Sovereign) ( 1 ) |
|
2004/C 289/4 |
Prior notification of a concentration (Case COMP/M.3605 — Sovion/HMG) ( 1 ) |
|
2004/C 289/5 |
Prior notification of a concentration (Case COMP/M.3651 — APAX/CINVEN/CBR) — Candidate case for simplified procedure ( 1 ) |
|
2004/C 289/6 |
Prior notification of a concentration (Case COMP/M.3634 — Isuzu/Bergé/Mitsubishi/JV) — Candidate case for simplified procedure ( 1 ) |
|
2004/C 289/7 |
||
2004/C 289/8 |
Notice published pursuant to Article 27(4) of Council Regulation (EC) No 1/2003 in Case COMP/A.39.116/B2 — Coca-Cola ( 1 ) |
|
2004/C 289/9 |
Non-opposition to a notified concentration (Case COMP/M.3446 — UNIQA/MANNHEIMER) ( 1 ) |
|
|
|
|
(1) Text with EEA relevance |
EN |
|
I Information
Commission
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/1 |
Euro exchange rates (1)
25 November 2004
(2004/C 289/01)
1 euro=
|
Currency |
Exchange rate |
USD |
US dollar |
1,3213 |
JPY |
Japanese yen |
135,75 |
DKK |
Danish krone |
7,4291 |
GBP |
Pound sterling |
0,70060 |
SEK |
Swedish krona |
8,9260 |
CHF |
Swiss franc |
1,5113 |
ISK |
Iceland króna |
87,04 |
NOK |
Norwegian krone |
8,1195 |
BGN |
Bulgarian lev |
1,9559 |
CYP |
Cyprus pound |
0,5791 |
CZK |
Czech koruna |
30,992 |
EEK |
Estonian kroon |
15,6466 |
HUF |
Hungarian forint |
245,73 |
LTL |
Lithuanian litas |
3,4528 |
LVL |
Latvian lats |
0,6844 |
MTL |
Maltese lira |
0,4328 |
PLN |
Polish zloty |
4,2174 |
ROL |
Romanian leu |
39 442 |
SIT |
Slovenian tolar |
239,79 |
SKK |
Slovak koruna |
39,255 |
TRL |
Turkish lira |
1 891 000 |
AUD |
Australian dollar |
1,6703 |
CAD |
Canadian dollar |
1,5572 |
HKD |
Hong Kong dollar |
10,2687 |
NZD |
New Zealand dollar |
1,8464 |
SGD |
Singapore dollar |
2,1675 |
KRW |
South Korean won |
1 396,88 |
ZAR |
South African rand |
7,7729 |
Source: reference exchange rate published by the ECB.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/2 |
Prior notification of a concentration
(Case COMP/M.3630 — Veolia/BVAG)
Candidate case for simplified procedure
(2004/C 289/02)
(Text with EEA relevance)
1. |
On 15 November 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Veolia Water Deutschland GmbH (‘Veolia’, Germany) controlled by Veolia Environment S.A. (France) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Braunschweiger Versorgungs-AG (‘BVAG’, Germany) by way of purchase of shares. |
2. |
The business activities of the undertakings concerned are:
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3630 — Veolia/BVAG, to the following address:
|
(2) Available on DG COMP website:
http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/3 |
Prior notification of a concentration
(Case COMP/M.3612 — Henkel/Sovereign)
(2004/C 289/03)
(Text with EEA relevance)
1. |
On 18 November 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Henkel KGaA (‘Henkel’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Sovereign Specialty Chemicals, Inc. (‘Sovereign’, U.S.A.). |
2. |
The business activities of the undertakings concerned are:
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3612 — Henkel/Sovereign, to the following address:
|
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/4 |
Prior notification of a concentration
(Case COMP/M.3605 — Sovion/HMG)
(2004/C 289/04)
(Text with EEA relevance)
1. |
On 18 November 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Sovion (‘Sovion’, The Netherlands) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Hendrix Meat Group (‘HMG’, The Netherlands) by way of purchase of shares |
2. |
The business activities of the undertakings concerned are:
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3605 — Sovion/HMG, to the following address:
|
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/5 |
Prior notification of a concentration
(Case COMP/M.3651 — APAX/CINVEN/CBR)
Candidate case for simplified procedure
(2004/C 289/05)
(Text with EEA relevance)
1. |
On 18 November 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Apax Europe V, an investment fund controlled by The Hirzell Trust (‘Apax’, Channel Islands) and Cinven Ltd. (‘Cinven’, UK) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertakings CBR Holding GmbH Co. KG, Street One GmbH Co. KG, Cecil GmbH Co. KG, One Touch GmbH Co. KG, CBR Companies GmbH Co. KG, Street One Markenrecht GmbH Co. KG, Cecil Markenrecht GmbH Co. KG and One Touch Markenrecht GmbH Co. KG (‘CBR Group’, Germany) by way of purchase of shares by Apax from Cinven. |
2. |
The business activities of the undertakings concerned are:
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3651 — APAX/CINVEN/CBR, to the following address:
|
(2) Available on DG COMP website:
http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/6 |
Prior notification of a concentration
(Case COMP/M.3634 — Isuzu/Bergé/Mitsubishi/JV)
Candidate case for simplified procedure
(2004/C 289/06)
(Text with EEA relevance)
1. |
On 18 November 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Bergé Automation S.L. (‘BA’, Spain), Isuzu Motors Ltd (‘Isuzu’, Japan), and Mitsubishi Corporation (‘Mitsubishi’, Japan) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking Distribuidora de Vehículos Isuzu Iberica S.A. (‘Isuzu Spain’, Spain) by way of purchase of shares. |
2. |
The business activities of the undertakings concerned are:
|
3. |
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
4. |
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3634 — Isuzu/Bergé/Mitsubishi/JV, to the following address:
|
(2) Available on DG COMP website:
http://europa.eu.int/comm/competition/mergers/legislation/consultation/simplified_tru.pdf.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/7 |
Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 October 2004 to 15 November 2004
(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) (1)
(2004/C 289/07)
Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93) — Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
22.10.2004 |
EMSELEX |
Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom |
EU/1/04/294/001-012 |
26.10.2004 |
22.10.2004 |
Mimpara |
Amgen Europe BV, Minervum 7061, 4817 ZK Breda, The Netherlands |
EU/1/04/292/001-012 |
26.10.2004 |
22.10.2004 |
Parareg |
Amgen Europe BV, Minervum 7061, 4817 ZK Breda, The Netherlands |
EU/1/04/293/001-012 |
26.10.2004 |
Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93) — Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
20.10.2004 |
Zeffix |
Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom |
EU/1/99/114/001-003 |
22.10.2004 |
||
20.10.2004 |
Puregon |
Organon NV, PO box 20, 5340 BH Oss, The Netherlands |
EU/1/96/008/038-039 |
22.10.2004 |
||
20.10.2004 |
Viracept |
Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom |
EU/1/97/054/001 EU/1/97/054/003-006 |
22.10.2004 |
||
20.10.2004 |
Taxotere |
Aventis Pharma SA, 20 avenue Raymond Aron, F-92165 Antony Cedex, |
EU/1/95/002/001-002 |
22.10.2004 |
||
20.10.2004 |
ViraferonPeg |
Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels |
EU/1/00/132/001-050 |
22.10.2004 |
||
20.10.2004 |
PegIntron |
Schering Plough Europe, Rue de Stalle, 73, B-1180 BrusselsStallestraat, 73, B-1180 Brussel |
EU/1/00/131/001-050 |
22.10.2004 |
||
22.10.2004 |
Herceptin |
Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom |
EU/1/00/145/001 |
26.10.2004 |
||
22.10.2004 |
EMEND |
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom |
EU/1/03/262/001-006 |
26.10.2004 |
||
22.10.2004 |
Sifrol |
Boehringer Ingelheim International GmbH, Binger Strasse 173 D-55216 Ingelheim am Rhein |
EU/1/97/050/001-006 EU/1/97/050/009-012 |
26.10.2004 |
||
22.10.2004 |
Bondronat |
Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom |
EU/1/96/012/001-013 |
26.10.2004 |
||
28.10.2004 |
Agenerase |
Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom |
EU/1/00/148/001-004 |
1.11.2004 |
||
28.10.2004 |
Paxene |
Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom |
EU/1/99/113/001-004 |
1.11.2004 |
||
28.10.2004 |
Cancidas |
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom |
EU/1/01/196/001-003 |
1.11.2004 |
||
28.10.2004 |
Ziagen |
Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom |
EU/1/99/112/001-002 |
1.11.2004 |
||
28.10.2004 |
Ziagen |
Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom |
EU/1/99/112/001-002 |
1.11.2004 |
||
28.10.2004 |
Ytracis |
CIS bio international, Boite postale 32, F-91192 Gif-sur-Yvette |
EU/1/03/250/001 |
3.11.2004 |
||
28.10.2004 |
Mirapexin |
Boehringer Ingelheim International GmbH, Binder Strasse 173, D-55216 Ingelheim am Rhein |
EU/1/97/051/001-006 EU/1/97/051/009-012 |
1.11.2004 |
||
28.10.2004 |
Viraferon |
|
EU/1/99/128/001-008 |
1.11.2004 |
||
28.10.2004 |
CoAprovel |
Sanofi Pharma Bristol-Myers Squibb SNC, 174 avenue de France, F-75013 Paris |
EU/1/98/086/001-020 |
2.11.2004 |
||
28.10.2004 |
Karvezide |
Bristol-Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow TW3 3JA, United Kingdom |
EU/1/98/085/001-020 |
1.11.2004 |
||
28.10.2004 |
Viread |
Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom |
EU/1/01/200/001 |
1.11.2004 |
||
28.10.2004 |
Ammonaps |
Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense |
EU/1/99/120/001-004 |
2.11.2004 |
||
28.10.2004 |
IntronA |
|
EU/1/99/127/001-010 EU/1/99/127/040 |
2.11.2004 |
||
29.10.2004 |
PEGASYS |
Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom |
EU/1/02/221/001-010 |
5.11.2004 |
||
29.10.2004 |
MabCampath |
ILEX Pharmaceutical Ltd, 1 & 3 Frederick Sanger Road, The Surrey Research Park, Guildford, Surrey GU2 7YD, United Kingdom |
EU/1/01/193/002 |
5.11.2004 |
||
29.10.2004 |
Liprolog |
Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands |
EU/1/01/195/001-015 |
5.11.2004 |
||
4.11.2004 |
Zometa |
Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom |
EU/1/01/176/001-006 |
8.11.2004 |
||
4.11.2004 |
Zyprexa |
Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands |
EU/1/96/022/002, EU/1/96/022/004, EU/1/96/022/006, EU/1/96/022/008-012, EU/1/96/022/014, EU/1/96/022/016-022 |
8.11.2004 |
||
4.11.2004 |
Zyprexa Velotab |
Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands |
EU/1/99/125/001-008 |
8.11.2004 |
||
4.11.2004 |
Zyprexa Velotab |
Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands |
EU/1/99/125/001-008 |
8.11.2004 |
||
9.11.2004 |
Vfend |
Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom |
EU/1/02/212/001-026 |
15.11.2004 |
||
12.11.2004 |
Arixtra |
Sanofi-Synthelabo 174 avenue de France, F-75013 Paris |
EU/1/02/206/009-017 |
16.11.2004 |
||
12.11.2004 |
Quixidar |
N.V. Organon PO box 20, Kloosterstraat 6, 5340 EB Oss, The Netherlands |
EU/1/02/207/009-017 |
16.11.2004 |
(1) OJ L 214, 24.8.1993, p. 1.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/10 |
Notice published pursuant to Article 27(4) of Council Regulation (EC) No 1/2003 in Case COMP/A.39.116/B2 — Coca-Cola
(2004/C 289/08)
(Text with EEA relevance)
1. Introduction
(1) |
The European Commission has received a set of commitments formally endorsed by ‘The Coca-Cola Company’ (TCCC) and its three most important bottlers in the EEA, ‘Coca-Cola Hellenic Bottling Company’, ‘Coca-Cola Enterprises’ and ‘Coca-Cola Erfrischungsgetränke AG’, together ‘the Companies’. These commitments have been made in the course of a Commission investigation into the Companies' business practices across the European Community, Norway and Iceland in the context of Article 82 of the EC Treaty and Article 54 of the EEA Agreement. |
(2) |
By means of the present publication, the Commission intends to market test the Companies' current proposal for commitments, which purport to address the Commission's competition concerns expressed in its preliminary assessment with regard to the investigated practices of the Companies. Subject to the outcome of the present market test, the Commission intends to adopt a decision pursuant to Article 9(1) of Council Regulation (EC) No 1/2003 of 16 December 2002 on the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty (1), to make those proposed commitments which meet the concerns expressed by the Commission in its preliminary assessment binding on the Companies. Such a decision would not conclude whether or not there has been or still is an infringement. |
2. Preliminary assessment
(3) |
The Commission has informed the Companies by letter of 18 October 2004 of its preliminary assessment within the meaning of Article 9(1) of Regulation (EC) No 1/2003. |
(4) |
Pursuant to the preliminary assessment, TCCC and its respective bottlers jointly hold a dominant position in certain of the national markets for the supply of carbonated soft drinks (CSDs) in the EC, Norway and Iceland and this in at least one of the two distribution channels: the take-home channel (supermarkets and other retail outlets), and the on-premises channel, also known as the away-from-home, horeca (catering) or gastronomy channel (2). |
(5) |
The practices raising concerns relate, with respect to both distribution channels, to exclusivity requirements, rebates granted on condition that the clients reach, on a quarterly basis, individually specified purchase thresholds separately set for colas and non-colas, tying arrangements and arrangements requiring the clients to carry for sale a range of cola stock-keeping units (SKUs) and/or non-cola SKUs. In the take-home channel, the Companies apply shelf space arrangements whereby the supermarkets reserve a large part of their CSD shelf space for TCCC-branded products. In the on-premises channel, customers receive up-front financing conditional upon their purchase of TCCC-branded products over a number of years. Moreover, the Companies have also attached certain exclusivity-related restrictions to the installation of technical sales equipments such as beverage coolers, fountain dispensers or vending machines. |
(6) |
According to the preliminary assessment, all practices have made access to the outlets more difficult for competitors to the ultimate detriment of consumers. The preliminary assessment noted in particular that the Companies could use the market power of their strong brands and the wide product portfolio as leverage to maintain and expand their market position. |
3. Commitments
(7) |
The commitments are briefly summarised in what follows and published in full in a non-confidential English version on the website of the Directorate-General for Competition: http://europa.eu.int/comm/competition/antitrust/cases/decisions/39116/tccc_final_undertaking_041019.pdf |
(8) |
The Companies propose to apply the commitments in all Member States, Norway and Iceland insofar as TCCC-branded CSDs accounted, in the previous year, for more than 40 %, and more than twice the share of the nearest competitor, of national CSD sales in either the take-home channel or the on-premises channel. |
(9) |
With respect to both distribution channels, the Companies commit:
|
(10) |
Specifically with respect to the take-home channel, the Companies commit:
|
(11) |
Specifically with respect to the on-premises channel, the Companies commit:
|
(12) |
Specifically with respect to commercial agreements in the on-premises channel entered into following competitive tendering, the Companies may impose exclusive beverage supply. When the tender is organised by large, private sector customers, the agreements will have a maximum duration of five years while giving customers, for the first time after three years, the annual option to terminate the agreement without penalty. The Companies will also limit the sales volume of tender agreements entered into with private customers that contain exclusive CSD supply rights to 5 % of the Companies' annual CSD sales in the on-premises channel. |
(13) |
Specifically with respect to the placement of technical sales equipment, the Companies commit:
|
4. The Commission's intention
(14) |
The Commission intends, subject to the outcome of this market test, to adopt a decision under Article 9(1) of Regulation (EC) No 1/2003 declaring those proposed commitments which meet the concerns expressed by the Commission in its preliminary assessment to be binding on the Companies. To this end, it invites interested third parties to submit their comments to it within one month of the publication of this notice. |
(15) |
Interested third parties are also asked to submit a non-confidential version of their comments, in which business secrets and other confidential passages are deleted and are if necessary replaced by a non-confidential summary or by the words ‘[business secrets]’ or ‘[confidential]’. |
(16) |
Comments should be sent to the following address, mentioning the reference ‘COMP/A.39.116/B2 — Coca-Cola’:
|
(2) Based on the data currently available (data for Cyprus, Luxembourg and Malta not yet available), the commitments would be applicable to: Austria, Belgium, Denmark, Estonia, France, Germany, Greece, Hungary (only take-home channel), Italy, Latvia, Lithuania (only take-home channel), the Netherlands, Norway (only take-home channel), Poland (only take-home channel), Spain, Sweden and the United Kingdom.
26.11.2004 |
EN |
Official Journal of the European Union |
C 289/13 |
Non-opposition to a notified concentration
(Case COMP/M.3446 — UNIQA/MANNHEIMER)
(2004/C 289/09)
(Text with EEA relevance)
On 28 June 2004, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in German and will be made public after it is cleared of any business secrets it may contain. It will be available:
— |
from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/) free of charge. This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
— |
in electronic form in the ‘CDE’ version of the CELEX database, under document number 32004M3446. CELEX is the computerized documentation system of European Community law. (http://europa.eu.int/celex) |